Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinod K Rustgi

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Clinics in Liver Disease|October 18, 2025
Current and Next-Generation Therapeutics in HepatologyVinod K Rustgi
Expert Opinion on Drug Safety|June 18, 2010
Safety of small molecules in combination with interferon-based therapy for hepatitis C virusVinod K Rustgi
Expert Review of Anti-Infective Therapy|November 26, 2005
Thymalfasin for the treatment of chronic hepatitis C infectionVinod K Rustgi
Clinics in Liver Disease|April 5, 2020
History of Hepatic EncephalopathyVinod K Rustgi
Current Medical Research and Opinion|March 12, 2009
Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis CVinod K Rustgi
Journal of Gastroenterology|July 27, 2007
The epidemiology of hepatitis C infection in the United StatesVinod K Rustgi
Clinics in Liver Disease|November 16, 2016
Drug-induced Hepatotoxicity…A Topic Where We Don't Know Enough!Vinod K Rustgi
Annals of the New York Academy of Sciences|June 30, 2007
Thymalfasin for the treatment of chronic hepatitis C infectionVinod K Rustgi
Clinics in Liver Disease|April 12, 2016
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver DiseaseSwaytha Ganesh, Vinod K Rustgi
Gastroenterology|October 13, 2006
Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enoughMitchell L Shiffman, Vinod K Rustgi
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Clinics in Liver Disease|October 18, 2025
Current and Next-Generation Therapeutics in HepatologyVinod K Rustgi
Expert Opinion on Drug Safety|June 18, 2010
Safety of small molecules in combination with interferon-based therapy for hepatitis C virusVinod K Rustgi
Expert Review of Anti-Infective Therapy|November 26, 2005
Thymalfasin for the treatment of chronic hepatitis C infectionVinod K Rustgi
Clinics in Liver Disease|April 5, 2020
History of Hepatic EncephalopathyVinod K Rustgi
Current Medical Research and Opinion|March 12, 2009
Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis CVinod K Rustgi
Journal of Gastroenterology|July 27, 2007
The epidemiology of hepatitis C infection in the United StatesVinod K Rustgi
Clinics in Liver Disease|November 16, 2016
Drug-induced Hepatotoxicity…A Topic Where We Don't Know Enough!Vinod K Rustgi
Annals of the New York Academy of Sciences|June 30, 2007
Thymalfasin for the treatment of chronic hepatitis C infectionVinod K Rustgi
Clinics in Liver Disease|April 12, 2016
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver DiseaseSwaytha Ganesh, Vinod K Rustgi
Gastroenterology|October 13, 2006
Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enoughMitchell L Shiffman, Vinod K Rustgi
Pageof 8